Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17418112 | 1.00 | SCN9A (0.49) | SCN9ASCN5AS1PR1CACNA1CCNR1 | |
| SCHEMBL16119809 | 0.86 | SCN9A (0.61) | SCN9ASCN5AS1PR1 | |
| SCHEMBL18400117 | 0.83 | SCN9A (0.36) | SCN9A | |
| SCHEMBL18400118 | 0.82 | SCN9A (0.35) | SCN9A | |
| SCHEMBL17418081 | 0.81 | SCN9A (0.54) | SCN9ASCN5AS1PR1CACNA1CCNR1 | |
| SCHEMBL16119833 | 0.81 | SCN9A (0.54) | SCN9ASCN5AS1PR1CACNA1CCNR1 | |
| SCHEMBL17433300 | 0.80 | SCN9A (0.35) | SCN9A | |
| SCHEMBL16119827 | 0.75 | SCN9A (0.46) | SCN9ASCN5AS1PR1CACNA1CCNR1 | |
| SCHEMBL17418127 | 0.75 | SCN9A (0.46) | SCN9ASCN5AS1PR1CACNA1CCNR1 | |
| SCHEMBL16094181 | 0.75 | SCN9A (0.46) | SCN9ASCN5AS1PR1CACNA1CCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | SCN9A 1460/4885SCN5A 425/4885S1PR1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.